SCHEMBL2122644

SCHEMBL2122644

COc1ccc(Nc2c(-c3ccc(OC)c(OC4CCCC4)c3)[nH]c3c(C#N)cnn23)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PRKCQ Q04759 4/20 0.43
▸ CSNK2A1 P68400 1/20 0.42
▸ TBK1 Q9UHD2 5/20 0.41
▸ PDE4A P27815 6/20 0.39
▸ PRKCH P24723 1/20 0.39
▸ PRKCE Q02156 1/20 0.39
▸ PRKCD Q05655 1/20 0.39
▸ PDE5A O76074 1/20 0.39
▸ PDE1A P54750 1/20 0.39
▸ PDE1B Q01064 1/20 0.39
▸ PDE1C Q14123 1/20 0.39
▸ PDE4B Q07343 5/20 0.39
▸ PDE4C Q08493 5/20 0.39
▸ PDE4D Q08499 5/20 0.39
▸ POLB P06746 1/20 0.39
▸ JAK2 O60674 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2127376 0.94 ROCK2 (0.40) PRKCQCSNK2A1TBK1PDE4APDE5A
SCHEMBL2125584 0.94 TBK1 (0.41) PRKCQCSNK2A1TBK1PDE4APDE5A
SCHEMBL2124742 0.92 TBK1 (0.42) PRKCQCSNK2A1TBK1PRKCHPRKCE
SCHEMBL2122770 0.88 TBK1 (0.38) PRKCQCSNK2A1TBK1JAK2
SCHEMBL2124161 0.85 PRKCQ (0.46) PRKCQCSNK2A1PRKCHPRKCEPRKCD
SCHEMBL2123111 0.85 CSNK2A1 (0.47) PRKCQCSNK2A1PRKCHPRKCEPRKCD
SCHEMBL2125606 0.84 CSNK2A1 (0.45) PRKCQCSNK2A1PRKCHPRKCEPRKCD
SCHEMBL2122879 0.84 PRKCQ (0.55) PRKCQCSNK2A1PRKCHPRKCEPRKCD
SCHEMBL2125701 0.83 CSNK2A1 (0.44) PRKCQCSNK2A1PRKCHPRKCEPRKCD
SCHEMBL2125314 0.83 PRKCQ (0.54) PRKCQCSNK2A1PRKCHPRKCEPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP claimed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US claimed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US claimed
EP-2827890-B1 IMMUNOMODULATORY AGENT AND USES THEREFOR UNIV QUEENSLAND (AU) 2019-08-28 — — EP disclosed
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-20150216955-A1 IMMUNOMODULATORY AGENT AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2015-08-06 — — US disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150216955-A1 IMMUNOMODULATORY AGENT AND USES THEREFOR HLA-DRB1, CD74, CHI3L1 PRKCQ 3208/4885CSNK2A1 4410/4885TBK1 4176/4885
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK PRKCQ 112/4885CSNK2A1 489/4885TBK1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback